Ivivi PEMF Technology Significantly Improves Tendon Repair in Laboratory Animals, the Journal of Hand Surgery Reports.

NORTHVALE, N.J. -- Ivivi Technologies, Inc. (AMEX: II) reported that research published in a recent issue of The Journal of Hand Surgery entitled "Pulsed Magnetic Field Therapy Increases Tensile Strength in Rat Achilles' Tendon Repair Model" has shown that Ivivi's recently developed noninvasive pulsed radio frequency electromagnetic fields (PEMF) can produce up to a 69% increase in rat Achilles' tendon breaking strength versus control tendons at 21 days after repair.

The study was conducted by a team of researchers consisting of Berish Strauch, MD, Mitesh K. Patel, MD, Daniel J. Rosen, MD, Soham Mahadevia, BA, Nelia Brindzei, BA, and Arthur A. Pilla, PhD.

"Pulsed electromagnetic fields hold promise as a safe, easily administered, non-invasive modality to accelerate and improve the body's healing mechanisms and this study speaks to the core competency of the technology," commented Dr. Pilla, Professor in Biomedical Engineering at Columbia University and Chairman of Ivivi Technologies' Scientific Advisory Board. "While historically, bone growth stimulators and other PEMF waveforms have shown few instances of clinical improvement in tendon or ligament repair, by specifically tuning the PEMF signal to target the Calcium/Calmodulin (Ca/CaM) pathway, known to be at the beginning of growth factor cascades involved in tissue healing, significant acceleration in tendon repair was seen. If similar effects occur in humans, rehabilitation could begin earlier and the risk of developing adhesions or rupturing the tendon in the early postoperative period could be reduced."

Information from this study is expected to be discussed at Ivivi's previously announced symposium on "The Science of Electroceuticals[TM]" to be held today, Tuesday, December 19, 2006 from 10:00 a.m. to 1:30 p.m. EST at The Corporate Auditorium in the McGraw-Hill Building, 1221 Avenue of the Americas, New York, New York. A webcast of the event will be available at http://www.wsw.com/webcast/ii/ or http://www.ivivitechnologies.com.

In this prospective, randomized, double-blind, and placebo-controlled study, the Achilles tendon of 40 young-adult male Sprague-Dawley rats were surgically transected and repaired. The rats were then divided into four treatment groups, three of which received specific PEMF treatments for two 30-minute sessions per day over a period of 3 weeks, while a single control group was treated identically except that no PEMF treatment was applied. At the end of the three week treatment period, tensile strength testing of the Achilles' tendon was performed. Results indicated an increase of up to 69% in tensile strength at the repair site of the rat Achilles' tendon in animals receiving PEMF exposure. In comparison, a non-significant 24% increase in tensile strength was observed with a non-thermal version of a pulsed radiofrequency PEMF signal used originally in diathermy. The study concludes that the application of electromagnetic fields, configured to enhance Ca2+ binding in the growth factor cascades involved in tissue healing, achieved a marked increase of tensile strength at the repair site in this animal model when compared to bone growth stimulator or diathermy based PEMF signals which had no significant effects.

About Ivivi Technologies, Inc.

Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals[TM] have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.

Forward-Looking Statements

This press release contains "forward looking statements" that are subject to risk and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's registration statement on Form SB-2. These risks could cause actual results to differ materially from those expressed in any forward looking statements made by, or on behalf of, the Company. The Company assumes no obligation to update the information contained in this press release.